Sara Varea

Suggest Changes
Learn More
BACKGROUND Autologous tumour lysate dendritic cell vaccine (ADC) has T-cell stimulatory capacity and, therefore, potential antitumour activity. We designed a phase II randomised trial of ADC + best(More)
  • 1